The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | How will novel agents affect the amyloidosis population?
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, and Raymond Comenzo MD, Tufts University School of Medicine, Boston, MA, discuss how novel agents will affect the standard treatment approach to amyloidosis. They also describe the recent approval of novel stabilizers and silencers, and how they can be implemented in conjunction with liver transplant in the treatment of hereditary amyloidosis. This roundtable was held at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
